VYONDYS 53 (golodirsen) - CAM 238

Description 
VYONDYS 53 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Dosage 

  • Measure glomerular filtration rate prior to initiation
  • 30 milligrams per kilogram once weekly
  • Administer as an intravenous infusion over 35 to 60 minutes
  • Dilution required prior to administration

Policy 
The efficacy of Vyondys 53™ (golodirsen) has not been clinically proven to improve muscle function or slow disease progression. It is investigational and/or unproven and therefore considered NOT MEDICALLY NECESSARY

Rationale 
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the VYONDYS 53 clinical development program, 58 patients received at least one intravenous dose of VYONDYS 53, ranging between 4 mg/kg (0.13 times the recommended dosage) and 30 mg/kg (the recommended dosage). All patients were male and had genetically confirmed Duchenne muscular dystrophy. Age at study entry was 6 to 13 years. Most (86%) patients were Caucasian.

VYONDYS 53 was studied in 2 double-blind, placebo-controlled studies.

In Study 1 Part 1, patients were randomized to receive once-weekly intravenous infusions of VYONDYS 53 (n=8) in four increasing dose levels from 4 mg/kg to 30 mg/kg or placebo (n=4), for at least 2 weeks at each level. All patients who participated in Study 1 Part 1 (n=12) were continued into Study 1 Part 2, an open-label extension, during which they received VYONDYS 53 at a dose of 30 mg/kg IV once weekly.

In Study 2, patients received VYONDYS 53 (n=33) 30 mg/kg or placebo (n=17) IV once weekly for up to 96 weeks, after which all patients received VYONDYS 53 at a dose of 30 mg/kg. 

Adverse reactions observed in at least 20% of treated patients in the placebo-controlled sections of Studies 1 and 2 are shown in Table 1.

Table 1: Adverse Reactions That Occurred in At Least 20% of VYONDYS 53-Treated Patients and at a Rate Greater than Placebo in Studies 1 and 2

Adverse Reaction

VYONDYS 53 (N = 41) %

Placebo (N = 21) %

Headache

41

10

Pyrexia

41

14

Fall

29

19

Abdominal pain

27

10

Nasopharyngitis

27

14

Cough

27

19

Vomiting

27

19

Nausea

20

10

Other adverse reactions that occurred at a frequency greater than 5% of VYONDYS 53-treated patients and at a greater frequency than placebo were: administration site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion, influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site-related reaction, constipation, and fracture.

Hypersensitivity reactions have occurred in patients treated with VYONDYS 53.

Clinical Studies
The effect of VYONDYS 53 on dystrophin production was evaluated in one study in DMD patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Study 1 Part 1 was a double-blind, placebo-controlled, dose-titration study in 12 DMD patients. Patients were randomized 2:1 to receive VYONDYS 53 or matching placebo. VYONDYS 53-treated patients received four escalating dose levels, ranging from 4 mg/kg/week (less than the recommended dosage) to 30 mg/kg/week by intravenous infusion for 2 weeks at each dose level.

Study 1 Part 2 was a 168-week, open-label study assessing the efficacy and safety of VYONDYS 53 at a dose of 30 mg/kg/week in the 12 patients enrolled in Part 1, plus 13 additional treatment-naive patients with DMD amenable to exon 53 skipping. At study entry (either in Part 1 or Part 2), patients had a median age of 8 years and were on a stable dose of corticosteroids for at least 6 months. Efficacy was assessed based on change from baseline in the dystrophin protein level (measured as % of the dystrophin level in healthy subjects, i.e., % of normal) at Week 48 of Part 2. Muscle biopsies were obtained at baseline prior to treatment and at Week 48 of Part 2 in all VYONDYS 53-treated patients (n=25) and were analyzed for dystrophin protein level by Western blot. Mean dystrophin levels increased from 0.10% (SD 0.07) of normal at baseline to 1.02% (SD 1.03) of normal by Week 48 of Study 1 Part 2, with a mean change in dystrophin of 0.92% (SD 1.01) of normal levels (p<0.001); the median change from baseline was 0.88%.

Individual patient dystrophin levels from Study 1 are shown in Table 2.

Table 2: Dystrophin Expression by Individual Patient From Study 1

Patient Number 

Western Blot % Normal Dystrophin

Patient number

Wester Blot % Normal Dystrophin

Baseline 

Part 2

Week 48   

Change from baseline 

Baseline 

 Part 2

Week 48

Change from baseline 

1

0.08

0.09

0.01

14

0.22

0.28

0.06

2

0.11

0.11

0.01

15

0.14

0.21

0.07

3

0.21

0.22

0.01

16

0.05

0.42

0.37

4

0.05

0.12

0.08

17

0.07

1.03

0.97

5

0.03

0.12

0.09

18

0.02

1.57

1.55

6

0.06

0.14

0.09

19

0.12

1.17

1.05

7

0.12

0.37

0.25

20

0.03

1.72

1.69

8

0.11

1.06

0.95

21

0.11

1.77

1.66

9

0.06

0.54

0.48

22

0.31

4.30

3.99

10

0.05

0.97

0.92

23

0.11

0.36

0.25

11

0.06

1.55

1.49

24

0.03

0.91

0.88

12

0.07

1.91

1.84

25

0.07

1.29

1.22

13 

0.10 

3.25 

3.15 

 

 

 

 

References 

  1. Vyondys 53 (golodirsen) [package insert] Sarepta Therapeutics December 2019
  2. U.S. Food and Drug Administration (FDA)  news release on agency's approval of Vyondys https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation  December 12, 2019

Coding Section 

Code Number Description
HCPCS J3490 Unclassified drugs
  J1429 (effective date 07/01/2020)  Injection, golodirsen, 10 mg 
ICD-10 G71.01 Duchenne or Becker muscular dystrophy

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive. 

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association.  All Rights Reserved" 

History From 2019 Forward     

12/22/2021 

Annual review, no change to policy intent. 

12/15/2020 

Annual review, no change to policy intent.

06/17/2020 

Updated coding. Added Code J1429 to be effective 7/1/2020. No other changes 

12/17/2019

New Policy

Complementary Content
${loading}